Company profile
Tanke Biosciences Corporation
OTC: TNBI · Financial Services · Asset Management
#526 of 1,012 Financial Services companies by revenue69th-percentile growth
EA Score
——FH —DQ 12GM —SS 39
v0.1 · 25/100 weight · pillars only
↑ balance-sheet leverage, revenue growth (YoY) · ↓ disclosure history, Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$210.2k
Employees
130
as of 2026-08-27
Market cap
$422.5k
as of 2026-08-27
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$28.6M$28.6M2012
Net income-$210.2k-$210.2k2012
Operating income$4.5M$4.5M2012
Total assets$28.8M$28.8M2012
Liabilities$12.9M$12.9M2012
Equity$15.8M$15.8M2012
Revenue trend
FY2011 – FY2012 · USD
FY11
FY12
FY12
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Tanke Biosciences Corporation’s revenue?
Tanke Biosciences Corporation booked $28.6M in FY2012 revenue, growing 20% year over year — faster than most Financial Services companies we track, at a -0.7% net margin.
Peers · Financial Services
Bar Harbor Bankshares48DOmni Financial Services, Inc.——Canadian Banc Corp.64CTriad Business Bank39DNexity Financial Corporation——Commercial National Financial Corporation51DNeighbors
Clark →Key facts
CEOVincent W. Renz Jr.
SectorFinancial Services
IndustryAsset Management
HeadquartersLas Vegas, NV
ExchangeOTC: TNBI
Employees130
IPO date2012-05-11
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.